Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -0.82% 121.50 120.00 123.00 123.50 121.50 123.50 20,437 10:07:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.0 -23.1 -8.4 - 188

Amryt Pharma Share Discussion Threads

Showing 5326 to 5347 of 5400 messages
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
DateSubjectAuthorDiscuss
12/12/2019
14:42
diamondstar As you say, the register was updated on 25th November to reflect the fact that another trial centre (Georgia from memory) had opened for recruitment. So I think it's fairly safe to assume that as of 25th November they were still recruiting. Even if they recruited the last patient immediately (unlikely)the 90 days treatment period would still take you to late February before the trial can be unblinded and the CRO can even start working on the data.
bermudashorts
12/12/2019
14:39
mdalos1 12 Dec '19 - 13:05 - 5196 of 5201 (Filtered)
papillon
12/12/2019
14:19
I understand why you are slightly more pessimistic on the timelines Bermuda - that’s because clinicaltrials.gov still states the study as recruiting. One possibility- similar to other trials I’ve been involved in - is that the Sponsor just hasn’t had time to update the website from recruiting to recruitment completed. That’s certainly a possibility, but the other one is that recruitment is truly behind, as you have postulated.
diamondstar1
12/12/2019
14:03
Thanks Bermuda. The Clinicaltrials.gov website was last updated by Amryt on 25 Nov 2019 - hence the information provided should be fairly accurate. In addition - they now have 53 sites involved in the study. In my estimation, they will be recruiting at 0.3 - 0.5 patients per site per month. This means that the study will likely be recruiting 15 - 25 EB patients per month. Therefore, even if their recruitment rate is at the lower end of the range (at 0.3 ps/pm) this will should only delay study completion by a couple of weeks. My Database Lock timelines (6 weeks) are also fairly long, and I have given 2 weeks for preparation for public disclosure. Therefore, I'm thinking early March, potentially late March if there are some delays in recruitment. But your Q2 estimate could be right Bermuda - only time will tell.
diamondstar1
12/12/2019
13:34
Diamondstar, Yes you're correct - will amended my 5197. However, they won't release results for primary endpoint in isolation - the database will only be closed and locked and then results produced once they reach the end of the main study - ie. when final patient has his/her final visit on day 90 of treatment. All IMO of course and I very much hope I'm wrong and you're right but I'm expecting results a little later than you (hopefully in Q2).
bermudashorts
12/12/2019
13:23
Bermuda, Primary Endpoint is wound healing at D45, rather than D90. Yes, patients will be treated for 90 days, but Primary Endpoint data will be collected earlier.
diamondstar1
12/12/2019
13:15
sidcam, Yes main study protocol is for a 90 day treatment period after which all patients, including those on the placebo arm join the open label follow up study for up to 2 years. The primary endpoint is measured at day 45 and the secondary at 90 days. So for Amryt to meet the primary endpoint timescale of Dec 2019 they would need to have recruited and started dosing the final patient 45 days beforehand. I don't believe that has happened - the study is still showing as recruiting. That's not at all surprising, recruitment for a paediatric rare disease like EB is never going to be an exact science, let alone when it's the largest ever trial ever undertaken.
bermudashorts
12/12/2019
12:36
Bermuda Are you sure it is 90 days? I recollect that was the time for the algereon study and that Amryt had a much shorter treatment cycle in their study.
sidam
12/12/2019
12:18
positivityNicholas 12 Dec '19 - 10:40 - 5189 of 5193 (Filtered) positivityNicholas 12 Dec '19 - 10:40 - 5190 of 5193 (Filtered)
papillon
12/12/2019
11:24
Think we'll have to agree to differ on this one.
bermudashorts
12/12/2019
11:14
Yes, Bermuda, clinicaltrials.gov indicates that last patient was recruited and target primary completion ie Primary Endpoint data collected is Dec 2019. I provided the info with simplistic wording - so most people can understand. This does not affect my overall rough projection - that full EASE will be disclosed around early March 2020.
diamondstar1
12/12/2019
10:49
diamondstar I'm not sure it's quite right to say that 'Clinicaltrials.gov indicates that last patient was recruited in Dec 2019'. The clinical trials register shows that the estimated primary completion date is Dec 2019 but that's not set in stone and to be honest I'd be very surprised if Amryt hit that timescale. Also primary completion date is when the final patient has completed treatment - ie. they're at the stage when they have all data for all patients. The treatment period is 90 days for each patient. Hopefully they're getting close and I would expect Amryt to issue an RNS when the study has closed for recruitment.
bermudashorts
12/12/2019
10:40
Papillon you are an aggressive straw in the wind, loser who likes winding people up . What you know about investing I could write on a stamp
positivitynicholas
12/12/2019
10:40
Papillon you are an aggressive straw in the wind, loser who likes winding people up . What you know about investing I could write on a stamp
positivitynicholas
12/12/2019
10:09
Thanks diamondstar1, very useful indeed Cheers!!
bazworth
12/12/2019
09:55
Just to clarify that we are not expecting the interim EASE results - we are waiting for the topline results from the full study. Clinicaltrials.gov indicates that last patient was recruited in Dec 2019. Add 6 weeks for data collection and database lock, and the flash results should be available in late Feb 2020. Amryt may take a couple of weeks to prepare for the press release etc, so the latest I expect the full EASE data is early March 2020.
diamondstar1
11/12/2019
18:18
mdalos's post has been deleted already and I didn't get the chance to read it! LOL. What's the point of posting MADLOSS if you delete them almost immediately? I see all your posts have been deleted. What's the point, MADLOSS, of posting? You need to seek help and urgently, though it's more than possible you're already in Broadmoor!
papillon
10/12/2019
17:52
papillon, be calm! It’s a bulletin board with folk hiding behind daft names. We’re just trying to make a few £bob. What others think is a total and absolute irrelevance!!
bazworth
10/12/2019
17:37
I have never ramped AMYT, bazworth, so I do lose my temper with MADLOSS when he suggests I have. I wont apologise for my reply. He's beneath contempt and I wont be nice to him. I hate him with a passion! MADLOSS originally suggested that AP101 had an 85% chance of failing phase3 based on a MIT research paper. However that paper included phase3 trial results for cancer treatments which have less than a 10% chance of success (CoS). When those cancer trial results are removed the CoS for a non cancer drug/treatment passing phase3 were much higher than 15%. Obviously MADLOSS wouldn't acknowledge that fact because he's a pathological liar. In fact for treatments such as AP101 the CoS is higher than 50%. In fact AP101 has already successfully passed phase3 trial, but only for wounds and not sp[ecifically for EB
papillon
10/12/2019
17:25
This is what I posted, MADLOSS, about the EASE interim readout result. I categorically state that the AP101 trial result is like gambling on roulette in a casino. papillon 4 Jan '19 - 11:46 - 4068 of 5180 Hence we must be getting the EASE Interim Readout before next Friday 11/1/2019. So sometime between next Monday and next Thursday. Probably Monday, or failing that Tuesday. Let's hope we get a good result and a significant increase in the AMYT share price A good result is DEFINITELY NOT GUARANTEED of course. Waiting for this Interim Readout is just like having placed all of your money on red, or black, in a casino and are waiting for the roulette wheel to stop! Sensible people with a big investment riding on this outcome might well have hedged their bets by now by de-risking but as I've only got just under £7k riding on the outcome I've kept all my shares and have made a few small additions since the 19th December. Fingers crossed I'm lucky. It's outside of my control so I'm not going to worry about it.
papillon
10/12/2019
17:25
Why on earth do you folks find it acceptable to be so incredibly rude to each other? Life is far too short folks! Smile & be happy!!
bazworth
10/12/2019
17:12
Statistically phase 111 should have a 65% success rate. So do not write it off at least for now.
sidam
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200226 11:20:32